Immunic, Inc. raised up to USD 400 million through a private placement led by BVF Partners L.P. to transition into a commercial-stage biotechnology company, enhancing its focus on MS therapies.
Amount Raised
$400 Million
Round Type
Post-IPO Equity
New YorkBiotechnologyInvestors
Description
Immunic, Inc. has announced an oversubscribed private placement with gross proceeds of up to USD 400 million, aimed at transforming the company into a commercial entity. This funding will support pivotal Phase 3 trials for its therapies targeting relapsing and progressive multiple sclerosis. BVF Partners L.P
Quick answer
Immunic Therapeutics raised $400 Million in a Post-IPO Equity round, dated February 13, 2026. Investors: RA Capital Management, Woodline Partners LP, Avidity Partners, Aberdeen Investments, Coastlands Capital, Vivo Capital, Tcgx and EcoR1 Capital. Immunic Therapeutics is based in New York, New York, United States.
- How much did Immunic Therapeutics raise?
- Immunic Therapeutics raised $400 Million in a Post-IPO Equity round on February 13, 2026.
- Who invested in Immunic Therapeutics?
- RA Capital Management, Woodline Partners LP, Avidity Partners, Aberdeen Investments, Coastlands Capital, Vivo Capital, Tcgx and EcoR1 Capital are named as investors in this round.
- What does Immunic Therapeutics do?
- Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
- Where is Immunic Therapeutics based and how big is it?
- Immunic Therapeutics is based in New York, New York, United States. Fundz records about 84 employees.
- Who are the decision-makers at Immunic Therapeutics?
- Fundz holds 1 contact at Immunic Therapeutics, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Immunic Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Neurolief raised $6M (Funding Round) on March 30, 2026.
- Oncomatryx Biopharma raised $67M (Corporate Round) on March 30, 2026.
- Centivax raised $37M (Funding Round) on March 30, 2026.
- Stratum Biosciences raised $2M (Seed) on March 30, 2026.
- Marvel Biosciences raised $476K (Grant) on March 30, 2026.
- FIZE Medical raised $6M (Series A) on March 30, 2026.
Who to call at Immunic Therapeutics, and when
A new round usually means Immunic Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Immunic Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immunic Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immunic Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immunic Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Immunic Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.